These data further support a regulatory effect of Ikaros on both IL7R and SH2B3 in ALL patients and suggested that Ikaros deletion is one of the mechanisms for high IL7R and low SH2B3 expression in the patients. The gene discussed is SH2B3; the disease is acute lymphoblastic leukemia.